71

Literaturverzeichnis

1. Reinhardt G., Seidel H.-J., Sonntag H.-G. et al .: "Ökologisches Stoffgebiet" . 1. Auflage Hippokrates , Stuttgart 1991

2. Robert Koch Institut ", Arbeitsgemeinschaft Bevölkerungsbezogener Krebsregister in Deutschland" , 2000

3. Forth W., Henschler D., Rummel W. et al .: "Pharmakologie und Toxikologie" . 6. Auflage Bibliographisches Institut & F.A. Brockhaus AG, Mannheim 1993

4. Weinshilboum R.M.: "The therapeutic revolution" . Clin Pharmacol Ther 1987 ; 42: 481

5. Karow T., Lang R.: "Pharmakologie und Toxikologie" . 7. Auflage Druckerei Hansen 1999, Pulheim

6. Storm G., Roerdink F.H., Steerenberg P.A. et al ".: Influence of lipid composition on the antitumour activity exerted by doxorubicin-containing liposomes in a rat solid tumour model." Cancer Res 1987 ; 47 : 3366

7. Storm G.,van Bloois L., Steerenberg P.A., et al ".: Liposome encapsulation of doxorubicin: pharmaceutical and therapeutic aspects" . J. Contrl. Release 1989 ; 9 : 215

8. Andreoni A., Colasanti A., Kisslinger A. et al ".: Fluorometric determination of the kinetics of anthracyclines uptake by cells" . J Biochem Biophys Meth 1993 ; 28 : 53- 68

9. Grochow L.B., Ames M.M .: A clinican´s guide to chemotherapy, pharmakokinetics and pharmacodynamic . William and Wilkins, Baltimore, Philadelphia, London 1998.

10. Di Marco A., Gaetani M., Dorigotti L. et al .: "Studi sperimentali sull´attivita´antineoplastica del nuovo antibiotico daunomicina." Tumori 1963 ; 49: 203-217

11. Dubost M., Ganter P., Maral R. et al .: Un nouvel antibiotique à propriétés cytostatique: la rubidomycine. C.R. Academie des Sciences 1963; 257: 1813-1815

12. Robert J.: Anthracyclines , in Grochow L.B. (Hrsg): "A clinican´s guide to chemotherapy, pharmacokinetics and pharmacodynamic" 1998 , S.93-131

13. Dorr R.T., Von Hoff D.D.: Cancer Chemotherapy Handbook . 2nd ed. Appleton & Lange , Norwalk 1994

72

15. Doroshow J.H .: Anthracyclines and Anthracenediones ", Chapter 17. Cancer Chemotherapy and Biotherapy" , 2nd ed., edited by Bruce A., Chabner and Dan L. Longo. Lippincott-Raven Publishers , Philadelphia 1996

16. Sweatman T.W., Israel M .: Anthracyclines ", Chapter 5. Cancer Therapeutics, Experimental and Clinical Agents," edited by B. A. Teicher 1997

17. Zeller W.J ".: Anthrazykline: Onkologie. Grundlagen, Diagnostik, Therapie und Entwick- lung" , Zur Hausen-Onkologie . Ecomed 2000; S. 1-20

18. Nagasawa K., Natazuka T., Nomiyama M. et al.: "Transport Mechanism of Anthracycline Derivates in Human Leukemia Cell line: Uptake and Efflux of Daunorubicin and Doxorubicin in HL60 and its Resistant Cells and Comparison with those of Pirarubicin" . Biol. Pharm. Bull . 1996; 19 :100-105

19. Forssen E.A., Malé-Brune R., Adler-Moore J.P. et al .: "Fluorescence Imaging Studies for the Disposition of Daunorubicin Liposomes (DaunoXome) within Tumor Tissue" . Cancer Research 1996; 56 : 2059-2065

20. Morjani H., Millot J.-M., Belhoussine R. et al.: "Anthracycline subcellular distribution in human leukemic cells by microspectrofluorometry: factors contributing to drug-induced cell death and reversal of multidrug resistance" . Leukemia 1997; 11: 1170-1179

21. Powis G ".: Anthracycline metabolism and free radical formation" , in: Powis G., Prough R. A. (Hrsg): Metabolism and action of anti-cancer drugs . Taylor & Francis , London 1987 ; S. 211- 260

22. Alberts D.S., Bachur N.R., Hotzman J.L ".:The pharmacokinetics of daunomycin in man" . Clin Pharmacol Ther 1971 ; 12 : 96-104

23. Huffman D.H., Bachur N.R. : "Daunorubicin metabolism in acute non-lymphozytic leukemia" . Blood 1972 b; 39 : 637-643

24. Rahmann A., Goodman A., Foo W ".: Clinical pharmacology of daunorubicin in phase I "

"patients with solid tumors: development of an analytic methodology for daunorubicin and its metabolits" . Semin Oncol 1984 ; 11 : 36-44

25. Possinger K., Hartenstein R., Ehrhart H ".: In-vitro Resistenztestung von Tumoren gegenüber Zytostatika" . Onkologie 1980 ; 6: 291-300

73

27. Possinger K., Wagner H., Worst P. et al.: "Oral Administration of Idarubicin as First Line Cytostatic Therapy in Patients with Metastasized Breast Cancer and Favourable Prognosis" . Onkologie 1991 ; 14: 31-34

28. Cusack B.J., Young S.P., Vestal R. et al ".: Age-related pharmacokinetics of daunorubicin and daunorubicinol following intravenous bolus daunorubicin administration in the rat." Cancer Chemother Pharmacol 1997 ; 39 : 505-512

29. Nielsen D., Maare C., Skovsgaard T ".: Cellular Resistance to Anthracyclines. Gen. Pharmac. (Vol. 27) 1996; 2: 251-255Cassidy J.: Pharmacokinetics, Targeting and Delivery Systems in Anthracycline-resistant Cancers" . European Journal of Cancer (Vol. 31 A) 1995 ; 7 : 18-20

30. Bogush T.,Smirnova G., Shubina I. et al.: "Direct evaluation of intracellular accumulation of free and polymer-bound anthracyclines" . Cancer Chemother Pharmacol 1995 ; 35 : 501-505

31. Bangham A.D., Standish M.M., Watkins J.C.: "Diffusion of univalent ions across the lamellae of swollen phospholipids." J. Mol. Biol . 1965 ; 13 : 238-252

32. Sessa G., Weissmann G ".: Phospholipid spherules (liposomes) as a model for biological membranes" . J. Lipid. Res . 1968 ; 9 : 310-318

33. Ranson M., Howell A., Cheeseman S ".: Liposomal drug delivery" . Cancer Treatment Reviews 1996; 22: 365-379

34. Storm G., Crommelin D.J.A ".: Colloidal Systems for Tumor Targeting" . Hybridoma (Vol. 16 ) 1997 ; 1 : 119-125

35. Allen T.M., Hansen C.B., Lopes D.E. et al ".: Pharmacokinetics of long-circulating liposomes" . Advanced Drug Delivery Reviews 1995 ; 16 : 267-284

36. Oku N., Namba Y.: "Long-Circulating Liposomes" . Critical Reviews in Therapeutic Drug Carrier Systems 1994; 11 (4 ): 231-270

37. Forssen E.A., Ross M. E.: "Daunoxome Treatment of Solid Tumors: Preclinical and Clinical Investigations" . Journal of Liposome Research 1994 ; 4 : 481-512

38. Sharma A., Sharma U.S.: "Liposomes in drug delivery: progress and limitations" . International Journal of Pharmaceutics 1997 ; 154 : 123-140

39. Massing U.: "Cancer therapy with liposomal formulations of anticancer drugs" . Int. J. Clin. Pharmacol. Ther. 1997 ; 35 : 87-90

74

40. Sargent J.M., Elgie A.W., Williamson C.J. et al ".: In Vitro Sensitivity to the Liposomal Preparation, DaunoXome in CLL" . Anticancer Research 1999 ; 19 : 3253-3258

41. Richardson D.S., Kelsey S.M., Johnson S.A.: "Early evaluation of liposomal daunorubicin (DaunoXome) in the treatment of relapsed and refractory lymphoma. Investigational" New Drugs 1997 ; 15: 247-253

42. Forssen E.A., Coulter D.M, Proffitt R.T.: "Selective In Vivo Localization of Daunorubicin Small Unilamellar Vesicals in Solid Tumors" . Cancer Research 1992 ; 52 : 3255-3261

43. Gill P.S., Espina B.M., Muggia F. et al .: "Phase I/II Clinical and Pharmacokinetic Evaluation of Liposomal Daunorubicin." Journal of Clinical Oncology (Vol.13 ) 1995 ; 4 : 996-1003

44. Yeo W., Chan K.K., Mukwaya G. et al ".: Phase II studies with DaunoXome in patients with nonresectable hepatocellular carcinoma: clinical and pharmacokinetic outcomes." Cancer Chemother Pharmacol 1999 ; 44: 124-130

45. Fumagalli L., Zucchetti M., Parisi I. et al ".: The pharmacokinetics of liposomal encapsulated daunorubicin are not modified by HAART in patients with HIV-associated Kaposi´s sarcoma" . Cancer Chemother Pharmacol 2000 ; 45 : 495-501

46. Ermacora A., Michieli M., Pea F. et al ".: Liposome encapsulated daunorubicin (daunoxome) for acute leukemia" . Haematologica 2000; Vol.85 (3 )

47. Pratt G., Wiles M.E., Rawstron A.C. et al.: "Liposomal Daunorubicin: In Vitro and In Vivo Efficacy In Multiple Myeloma" . Hematological Oncology 1998 ; 16 : 47-55

Research Reports : "Daunoxome Data Presented at International Cancer Meeting. " Oncology (Vol. 10 ) 1996 ; 6: 830

48. Rahman A., Husai S.R., Siddiqui J. et al ".: Liposome -Mediated Modulation of Multidrug Resistance in Human HL-60 Leukemia Cells" . J Natl Cancer Inst 1992 ; 84 : 1909-1915

49. Van Engeland M., Nieland L.J.W., Ramaekers F.C.S ".: Annexin V-Affinity Assay: A Review on an Apoptosis Detection System Based on Phosphatidylserine Exposure" . Cytometry 1998 ; 31 : 1-9

50. Thomas C .: Histopathologie . 12.Auflage, Schattauer , Stuttgart 1998.

51. Bogensberger S., Boss N., Büttner M. et al .: Roche Lexikon Medizin 4.Auflage. Urban & Schwarzenberg , München 1999

75

53. Gieseler F., Biersack H., Brieden T. et al .: "Cytotoxicity of anthracyclins: correlation with cellular uptake, intracellular distribution and DNA binding" . Ann Hematol 1994 ; 69 : 13-17

54. Gieseler F., Nüßler V., Brieden T., et al ".: Intracellular pharmacokinetics of anthracyclines in human leukemia calls: correlation of DNA-binding with apoptotic cell death" . Int J Clin Pharmacol Ther (Vol. 1 ) 1997 ; 36: 25-28

55. Negri C., Bernardi R., Donzelli M. et al ".: Induction of apoptotic cell death by DNA topoisomerase II inhibitor." Biochimi 1995; 77 : 893-899

56. Solary E., Bertrand R., Pommier Y ".: Apoptosis induced by DNA topoisomerase I and II inhibitors in human leukemic HL 60 cells" . Leuk Lymphoma 1994 ; 15 : 21-32

57. Darzynkiewicz Z., Juan G., Li X. et al.: "Cytometry in Cell Necrobiology: Analysis of Apoptosis and Accidental Cell Death (Necrosis)." Cytometry 1997 ; 27 : 1-20

58. Garland J.M., Halestrap A .: "Energy Metabolism during Apoptosis" . The Journal of Biological Chemistry (Vol. 272 ) 1997 ; 8 : 4680-4688

59. Shidoji Y., Nakamura N., Moriwaki H. et al.: "Rapid Loss in Mitochondrial Membrane Potential during Geranylgeranoic Acid-Induced Apoptosis" . Biochemical and Biophysical Research Communications 1997 ; 230 : 58-63

60. Hess K.L., Babcock G.F., Askew D.S. et al ".: A Novel Cytometric Method for Quantifying Phagocytosis of Apoptotic Cells" . Cytometry 1997 ; 27 : 145-152

61. Hara S., Dorota H., Bruno S. et al ".: Effect of Protease Inhibitors on Early Events of Apoptosis." Experimental Cell research 1996 ; 223 : 372-384

62. Gorman A.M., Samali A., McGowan A.J. et al .: "Use of Flow Cytometry Techniques in Studying Mechanisms of Apoptosis in Leukemic Cells" . Cytometry 1997 ; 29: 97-105

63. Wadia J.S., Chalmers-Redman R.M.E., Ju W.J.H. et al ".: Mitochondrial Membrane Potential and Nuclear Changes in Apoptosis Caused by Serum and Nerve Growth Factor Withdrawel: Time Course and Modification by (-) -Deprenyl" . The Journal of Neuroscience (Vol. 3 ) 1998 ; 18 : 932-947

64. Waring P., Beaver J.: "Cyclosporin A Rescue Thymocytes from Apoptosis Induced by Very Low Concentrations of Thapsigargin: Effects on Mitochondrial Function" . Experimental Cell Reseach 1996 ; 227: 264-276

76

66. Ferlini C., Di Cesare S., Rainaldi G. et al.: "Flow Cytometric Analysis of the Early Phases of Apoptosis by Cellular and Nuclear Techniques" . Cytometry 1996 ; 24 : 106-115

67. Foley G.E., Lazarus, Farber S. et al.: "Continuous culture of human lymphoblasts from peripheral blood of a child with acute leukemia" . Cancer 1965; 18 : 522-529

68. Tarasiuk J., Foucrier J., Garnier-Suillerot A ".: Cell cycle dependent uptake and release anthracycline by drug-resistent and drug-sensitive human leukaemic K62 cells" . Biochem.Pharmacol . 1993 ; 45 (9 ): 1801-1808

69. Mc Gown A.T., Ward T.H., Fox B.W ".: Comparative Studies on the Uptake of Daunorubicin in Sensitive and Resistant P388 Cell Lines by Flow Cytometry and Biochemical Extraction Procedures" . Cancer Chemother Pharmacol 1983 ; 11 : 113-116

70. Flath B., Possinger K ".: Wert der Durchflußzytometrie bei der Diagnostik und Verlaufsbeurteilung von Leukämien und Lymphomen" . Krebs 1997 ; 16 (1 ): 16-21

71. Raffael A., Nebe C.Th., Valet G.: "Grundlagen der Durchflußzytometrie" in Schmitz-Rothe (Hrsg ): Durchflußzytometrie in der klinischen Zelldiagnostik . Schattauer , Stuttgart 1994 , S. 3-48

72. Jaroszeski M.J., Radcliff G.: "Fundamentals of Flow Cytometry" . Molecular Biotechnology 1999 ; 11 : 37-53

73. Longobardi Givan A.: Flow Cytometry: First Principals . Wiley-Liss, Inc ., New York 1992

74. Inoué S.: "Foundations of Confocal Scanned Imaging in Light Microscopy" in Pawley J.B.(Hrsg): Handbook of Biological Confocal Microscopy . Plenum Press , New York 1990 , S. 1-14

75. Sheppard C.J.R.: "Confocal Microscopy: Basic Principals and System Performance" in Cheng P.C., Lin T.H., Wu W.L. et al. (Hrsg): Multidimensional Microscopy . Springer, New York 1994 , S. 1-31

76. Gratton E., Van De Ven M.J. : "Laser Source for Confocal Microscopy" in Pawley J.B.(Hrsg): Handbook of Biological Confocal Microscopy . Plenum Press , New York 1990, S. 53-67

77

78. Stelzer E.H.K.: "The Intermediate Optical System of Laser Scanning Confocal Microscopes in" Pawley J.B.(Hrsg ): Handbook of Biological Confocal Microscopy . Plenum Press , New York 1990 ,S. 93-103

79. Wells K.S ".: Quantitative Fluorescence Imaging with Laser Scanning Confocal Microscopy" in Pawley J.B.(Hrsg): Handbook of Biological Confocal Microscopy . Plenum Press , New York 1990 ,S. 27-39

80. Nagasawa K., Takara K., Nomiyama M. et al.: "Transport Mechanisms of Anthracycline Derivates in Human Leukemia Cell lines: Uptake of Pirarubicin, Daunorubicin and Doxorubicin by K562 and Multidrug-Resistant K562/ADM Cells." Biol. Pharm. Bull . (Vol. 7 ) 1996 ; 19 : 971-976

81. Serafino A., Sinibaldi-Vallebona P., Pierimarchi P. et al ".: Induction of Apoptosis in Neoplastic Cells by Anthracycline Antitumor Drugs: Nuclear and Cytoplasmatic Triggering?." Anticancer Research 1999 ; 19: 1909-1918

82. Serafino A., Sinibaldi-Vallebona P., Gaudiano G. et al .: "Cytoplasmatic localisation of anthracycline antitumor drugs conjugated with reduced glutathione: a possible correlation with multidrug resistant mechanisms" . Anticancer Res 1998 ; 18 : 1159-1166

83. Forssen E., Chan K.K., Muggia F.M. et al ".: Clinical pharmacokinetics of liposomal daunorubicin." Proc Am Assoc Cancer Res 1990 ; 31 : 181

"Research Reports: Daunoxome an “Active Agent“ in Patients with Relapsed or Refractory NHL, Say Independent Investigators" . Oncology (Vol. 10 ) 1996 ; 12 : 1856

84. Lautier D., Bailly J.-D., Demur C. et al.: "Altered Intracellular Distribution of Daunorubicin in Immature Acute Myeloid Leukemia Cells." Int. J. Cancer 1997 ; 71 : 292-299

85. Chiodini B., Bassan R., Barbui T.: "Cellular Uptake and Antiproliferative Effects of Therapeutic Concentrations of Idarubicin or Daunorubicin and their Alcohol Metabolites, with or without Cyclosporin A, in MDR1+ Human Leukemic cells." Leukemia and Lymphoma 1999 ; 33 (5-6 ): 485-497

86. Nooter K., Oostrum R., Jonker R. et al.: "Effect of cyclosporin A on daunorubicin accumulation in multidrug-resistent P388 leukemic cells measured by real-time flow cytometry. " Cancer Chemother Pharmacol 1989 ; 23 : 296-300

78

88. Maciorowski Z., Delic J., Padoy E. et al.: "Comparative Analysis of Apoptosis Measured by Hoechst and Flow Cytometry in NHL" . Cytometry 1998 ; 32 : 44-50

© Die inhaltliche Zusammenstellung und Aufmachung dieser Publikation sowie die elektronische Verarbeitung sind urheberrechtlich geschützt. Jede Verwertung, die nicht ausdrücklich vom Urheberrechtsgesetz zugelassen ist, bedarf der vorherigen Zustimmung. Das gilt insbesondere für die Vervielfältigung, die Bearbeitung und Einspeicherung und Verarbeitung in elektronische Systeme.